1. Das L, Meghana A, Paul P, Ghosh S. Are We Ready For Covid–19 Vaccines?–A General Side Effects Overview. Journal of Current Medical Research and Opinion. 2021;4(02).
2. Griffiths D, Sheehan L, van Vreden C, Petrie D, Grant G, Whiteford P, et al. The Impact of Work Loss on Mental and Physical Health During the COVID-19 Pandemic: Baseline Findings from a Prospective Cohort Study. Journal of occupational rehabilitation. 2021:1-8.
3. Miller DJ, Capodilupo JV, Lastella M, Sargent C, Roach GD, Lee VH, et al. Analyzing changes in respiratory rate to predict the risk of COVID-19 infection. PLoS One. 2020;15(12):e0243693.
4. Yanes-Lane M, Winters N, Fregonese F, Bastos M, Perlman-Arrow S, Campbell JR, et al. Proportion of asymptomatic infection among COVID-19 positive persons and their transmission potential: A systematic review and meta-analysis. PloS one. 2020;15(11):e0241536.
5. Hale T, Angrist N, Goldszmidt R, Kira B, Petherick A, Phillips T, et al. A global panel database of pandemic policies (Oxford COVID-19 Government Response Tracker). Nature Human Behaviour. 2021;5(4):529-38.
6. Salathe M, Kazandjieva M, Lee JW, Levis P, Feldman MW, Jones JH. A high-resolution human contact network for infectious disease transmission. Proceedings of the National Academy of Sciences. 2010;107(51):22020-5.
7. Yan Y, Pang Y, Lyu Z, Wang R, Wu X, You C, et al. The COVID-19 vaccines: recent development, challenges and prospects. Vaccines. 2021;9(4):349.
8. Strohfus PK, Brown SR, Potratz P. Effective and sustainable advice line promotes safe vaccine practices. International journal of evidence-based healthcare. 2016;14(3-4):130-5.
9. Dhama K, Sharun K, Tiwari R, Dhawan M, Emran TB, Rabaan AA, et al. COVID-19 vaccine hesitancy–reasons and solutions to achieve a successful global vaccination campaign to tackle the ongoing pandemic. Human Vaccines & Immunotherapeutics. 2021:1-5.
10. Wilson SL, Wiysonge C. Social media and vaccine hesitancy. BMJ Global Health. 2020;5(10):e004206.
11. Jefferson T. Real or perceived adverse effects of vaccines and the media—a tale of our times. BMJ Publishing Group Ltd; 2000.
12. Banzhoff A, Nacci P, Podda A. A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis. Gerontology. 2003;49(3):177-84.
13. Flanagan KL, Klein SL, Skakkebaek NE, Marriott I, Marchant A, Selin L, et al. Sex differences in the vaccine-specific and non-targeted effects of vaccines. Vaccine. 2011;29(13):2349-54.
14. Giefing‐Kroll C, Berger P, Lepperdinger G, Grubeck‐Loebenstein B. How sex and age affect immune responses, susceptibility to infections, and response to vaccination. Aging cell. 2015;14(3):309-21.
15. Saleska JL, Choi KR. A behavioral economics perspective on the COVID-19 vaccine amid public mistrust. Translational behavioral medicine. 2021;11(3):821-5.
16. Amit S, Beni SA, Biber A, Grinberg A, Leshem E, Regev-Yochay G. Postvaccination COVID-19 among Healthcare Workers, Israel. Emerging Infectious Diseases. 2021;27(4):1220.
17. Joshi U, Singh P. Adverse reaction following COVISHEILD a covid 19 vaccine-Experience of from a single Centre. 2021.
18. Meo S, Bukhari I, Akram J, Meo A, Klonoff D. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. Eur Rev Med Pharmacol Sci. 2021;25(3):1663-9.
19. Arkin H, Colton RR. Tables for statisticians. Barnes and Noble. Inc, New York. 1963;168.
20. Jayadevan R, Shenoy RS, Anithadevi T. Survey of symptoms following COVID-19 vaccination in India. medRxiv. 2021.
21. Sah R, Shrestha S, Mehta R, Sah SK, Raaban AR, Dharma K, et al. AZD1222 (Covishield) vaccination for COVID-19: Experiences, challenges and solutions in Nepal. Travel Medicine and Infectious Disease. 2021.
22. Shrestha S, Devbhandari RP, Shrestha A, Aryal S, Rajbhandari P, Shakya B, et al. Adverse events following the first dose of ChAdOx1 nCoV-19 (COVISHIELD) vaccine in the first phase of vaccine roll out in Nepal. Journal of Patan Academy of Health Sciences. 2021;8(1):9-17.
23. R-CoreTeam. R: A language and environment for statistical computing. R Foundation for Statistical Computing; 2020.
24. Krammer F, Srivastava K, Simon V. Robust spike antibody responses and increased reactogenicity in seropositive individuals after a single dose of SARS-CoV-2 mRNA vaccine. MedRxiv. 2021.
25. Turner PJ, Ansotegui IJ, Campbell DE, Cardona V, Ebisawa M, Yehia E-G, et al. COVID-19 vaccine-associated anaphylaxis: a statement of the World Allergy Organization Anaphylaxis Committee. World Allergy Organization Journal. 2021:100517.
26. Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. The Lancet. 2020;396(10267):1979-93.
27. Potluri T, Fink AL, Sylvia KE, Dhakal S, Vermillion MS, Vom Steeg L, et al. Age-associated changes in the impact of sex steroids on influenza vaccine responses in males and females. npj Vaccines. 2019;4(1):1-12.
28. Gee J. First month of COVID-19 vaccine safety monitoring—United States, December 14, 2020–January 13, 2021. MMWR Morbidity and mortality weekly report. 2021;70.
29. Blumenthal KG, Robinson LB, Camargo CA, Shenoy ES, Banerji A, Landman AB, et al. Acute allergic reactions to mRNA COVID-19 vaccines. Jama. 2021;325(15):1562-5.
30. Remlabeevi A, Mathew T, Nair H, Nair GLR, Alex MR. Adverse events and their association with comorbidities after first and second doses of Covishield vaccination among healthcare workers of Government owned medical colleges in Kerala. medRxiv. 2021.
31. Shah SB, Chawla R, Mehta A. SARS-CoV-2: Comparison of Active Immunity Acquired by Natural Exposure versus Inoculation of HCW. Galore International Journal of Health Sciences and Research. 2021;6(2):54-63.
32. GoN/CBS. Report on the Nepal Labour Force Survey 2017/18. 2019.
33. Aryal KK, Mehata S, Neupane S, Vaidya A, Dhimal M, Dhakal P, et al. The burden and determinants of non communicable diseases risk factors in Nepal: findings from a nationwide STEPS survey. PloS one. 2015;10(8):e0134834.